NCT03284593进行中（未招募）不适用
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 199
- 试验地点
- 2
- 主要终点
- Survival
研究概览
简要总结
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with acute myeloid leukemia
排除标准
- 未提供
研究组 & 干预措施
intensive chemotherapy group
patients treated with intensive chemotherapy
干预措施: intensive chemotherapy (Drug)
Azacitidine group
patients treated with azacitidine
干预措施: Azacitidine (Drug)
结局指标
主要结局
Survival
时间窗: 2 years
Survival times
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
4 期
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRAcute Myeloid LeukemiaNCT06571825He Huang118
尚未招募
不适用
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine HospitalAcute Myeloid LeukemiaNCT05558943Assistance Publique - Hôpitaux de Paris750
Unknown
2 期
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML PatientsAcute Myeloid LeukemiaNCT03045627Shandong University120
进行中（未招募）
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-GBCardiff University2,000
进行中（未招募）
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-DKCardiff University2,000